The Clinical Advisory Board (CAB) will organise a consensus meeting with WP2, WP3, WP5, and patient organisations to define inclusion and exclusion criteria for the new patient cohort (Major Depressive Disorder, MDD). Furthermore, it will review the Schizophrenia (SZ) and Alzheimer Disease (AD) inclusion and exclusion criteria from PRISM in light of the newly added digital technologies, provide support to PRISM 2 members concerning the “PRISM 2 – VALIDATE” study, and review and assess the results of the interim evaluation.
Prof. Dr. Brenda Penninx
Professor of Psychiatric Epidemiology
Phone: +31 (0)20 788 567 4
Dr. Thomas Tzschentke
Senior Translational Medicine & Clinical Biomarker Lead – CNS Diseases
The Scientific and Ethical Advisory Board (SEAB) is a consultative body which is formed to ensure the highest possible scientific performance, adherence to ethics requirements, and the overall quality of PRISM 2 results. The following renowned experts from relevant scientific fields have agreed to be part of the PRISM 2 SEAB.
Prof. Dr. Deanna Barch
Departments of Psychology, Psychiatry, and Radiology
Washington University, WA, USA
The Impact and Innovation Board (IIB) together with ECNP will be responsible for designing a structured plan for dissemination and communication and overseeing the exploitation of programme results by monitoring the steps being taken. Together with the COOR-team it will oversee the comprehensive internal and external dissemination of project results and knowledge. Importantly, prior to every general assembly (GA) meeting, every site principal investigator (PI) of PRISM 2 will be interviewed about their plans for dissemination in the coming year, and whether any new intellectual property (IP) emerged that may need protection.
